Opendata, web and dolomites

EpiTarget

Epigenome-targeted therapy for cholangiocarcinoma.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 EpiTarget project word cloud

Explore the words cloud of the EpiTarget project. It provides you a very rough idea of what is the project "EpiTarget" about.

vivo    treatment    screen    draw    turning    translational    lesions    myself    enzymes    malignancy    expert    data    molecular    surviving    genomics    abysmal    patients    versus    rescue    virtually    scientific    diagnosis    transferable    architecture    reversible    vitro    world    point    clinic    cellular    demographic    deep    escalating    view    cholangiocarcinoma    extensively    acting    crispr    curative    first    therapeutic    clarify    cholangiocarcinogenesis    epigenomic    patient    underpin    epimutations    gt    achilles    independent    neoplastic    sexes    accordingly    accomplishment    expansive    devastating    mutations    phenotypic       intractable    mortality    epimutation    chemotherapy    supervised    skills    optimal    rates    broaden    models    editing    manipulation    unlike    global    bio    for    benefit    expertise    dr    plan    exacerbating    carry    heel    bank    clinical    deluge    70    cancer    greatest    sequencing    epigenetic    jesper    epi    prognosis    compare    anti    andersen    therapy    intrinsically    epigenomics    breaking    time    hepatobiliary    prompting    drug    unmet    recurrent    epigenome    palliative    researcher    cca    comprise    enzymatic    streamline   

Project "EpiTarget" data sheet

The following table provides information about the project.

Coordinator
KOBENHAVNS UNIVERSITET 

Organization address
address: NORREGADE 10
city: KOBENHAVN
postcode: 1165
website: www.ku.dk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Denmark [DK]
 Project website https://www.bric.ku.dk/Research/andersen-group/
 Total cost 200˙194 €
 EC max contribution 200˙194 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2015
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2017
 Duration (year-month-day) from 2017-02-01   to  2019-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    KOBENHAVNS UNIVERSITET DK (KOBENHAVN) coordinator 200˙194.00

Map

 Project objective

For > 70% of cholangiocarcinoma (CCA) patients, no curative treatment is available at time of diagnosis and they proceed directly to palliative chemotherapy with virtually 0% surviving at 5 years. Breaking overall cancer trends, CCA mortality rates are escalating among both sexes in the EU, exacerbating this clinical demographic of intractable patients. Recently, a deluge of deep sequencing studies have identified recurrent mutations in epigenetic enzymes in CCA, prompting a turning point in our view of the molecular architecture of this devastating malignancy. Unlike traditional mutations, epigenetic lesions or ‘epimutations’ are intrinsically reversible and, therefore, may comprise an optimal Achilles heel to target for therapeutic benefit. However, to streamline epigenome-driven therapy to the clinic, we first need to clarify molecular and cellular responses to epigenetic manipulation in different CCA models. Accordingly, I have 3 specific objectives of this proposal: i) I plan to carry out a comprehensive in vitro epi-drug screen to determine which enzymatic targets have the greatest anti-neoplastic activity; from this, ii) I will characterize the epigenomic changes that underpin such phenotypic rescue; finally, iii) I will compare the therapeutic effects of the top global-acting epi-drug versus target-specific epigenetic editing (Epi-CRISPR) of the most recurrent epimutation in vivo. Accomplishment of these objectives will improve our understanding of cholangiocarcinogenesis and also address the unmet clinical need for novel therapeutic targets in this cancer demographic with abysmal prognosis. The project will be supervised by Dr. Jesper Andersen, a world-leading expert in hepatobiliary cancer genomics, and will draw extensively on his expansive patient bio- and data-bank. Through this work, I aim to broaden my scientific expertise (including technical and transferable skills) and to establish myself as an independent researcher in translational epigenomics.

 Publications

year authors and title journal last update
List of publications.
2018 Chirag Nepal Colm J. O\'Rourke Douglas V.N.P. Oliveira Andrzej Taranta Steven Shema Prson Gautam Julien Calderaro Andrew Barbour Chiara Raggi Krister Wennerberg Xin W. Wang Anja Lautem Lewis R. Roberts Jesper B. Andersen
Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma
published pages: 949-963, ISSN: 1527-3350, DOI:
Hepatology 68(3) 2019-09-02
2018 Colm J.O\'Rourke, Patricia Munoz-Garrido, Esmeralda L.Aguayo, Jesper B.Andersen
Epigenome dysregulation in cholangiocarcinoma
published pages: 1423-1434, ISSN: 0925-4439, DOI:
Biochimica et biophysica acta - Molecular basis of disease Volume 1864, Issue 4, Part B 2019-09-02

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EPITARGET" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EPITARGET" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

MacMeninges (2019)

Control of Central Nervous Sytem inflammation by meningeal macrophages, and its impairment upon aging

Read More  

IMPRESS (2019)

Integrated Modular Power Conversion for Renewable Energy Systems with Storage

Read More  

5G-ACE (2019)

Beyond 5G: 3D Network Modelling for THz-based Ultra-Fast Small Cells

Read More